Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day
Objective: Evaluate the effect of investigational ND0612 infusion on the daily number of, duration of, and transitions between PD motor states, as assessed by home…Programming Adaptive Deep Brain Stimulation in the Clinic: Lessons from the ADAPT-PD Trial
Objective: To present data and lessons learned from the ADAPT-PD trial Background: Adaptive deep brain stimulation (aDBS) will require strategies for efficient and effective aDBS…The Effect of Stochastic Resonance Stimulation in Neural Control of Balance During Walking in Parkinson Disease
Objective: This study aimed to investigate the effect of stochastic resonance (SR) stimulation on balance control during visually perturbed walking in people with Parkinson disease…Effect of Levodopa therapy in Hypokinetic Dysarthria in Parkinson’s Disease
Objective: The objective of this study was to assess the possible changes in acoustic speech parameters in a cohort of PD patients after acute levodopa…Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)
Objective: To determine the effectiveness of photobiomodulation (light therapy) on MDS-UPDRS-III scores over a five-year period Background: As a progressive neurodegenerative disease, worsening of motor…The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial
Objective: To assess the therapeutic effect of DL-3-n-butylphthalide on cognitive impairment associated with Parkinson’s disease (PD). Background: PD associated cognitive impairment are attracting attention because…The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.
Objective: Understanding the biological link between alpha-synuclein biomarker changes and clinical outcome using computer simulation. Background: A number of disease modifying therapeutic interventions focused on…Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies
Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease
Objective: The aim of this observational study for PD patients treated with foslevodopa/foscarbidopa(LDP/CDP) is to evaluate clinical characteristics, therapeutic efficacy and safety, and to determine…Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability
Objective: We performed a pilot study looking at the safety and tolerability of Faecal Microbiota Transplantation, its effect on the microbiome, and improvement of symptoms…
- « Previous Page
- 1
- …
- 166
- 167
- 168
- 169
- 170
- …
- 181
- Next Page »